FDA approves lisocabtagene maraleucel (liso-cel or JCAR-017) a CAR-T cell therapy for relapsed or refractory large B-cell lymphoma
September 7, 2016 – The Blue Ribbon Panel report presented to the National Cancer Advisory Board describing its 10 transformative research recommendations for achieving the Cancer Moonshot’s goal of making a decade’s worth of cancer research progress in 5 years. When implemented, the recommendations will advance critical areas of research to prevent and treat cancer. Their recommendations include:
- Establish a network for direct patient involvement
- Create a clinical trials network devoted exclusively to immunotherapy
- Develop ways to overcome resistance to therapy
- Build a national cancer data ecosystem
- Intensify research on the major drivers of childhood cancers
- Minimize cancer treatment’s debilitating side effects
- Expand use of proven prevention and early detection strategies
- Mine past patient data to predict future patient outcomes
- Develop a 3D cancer atlas
- Develop new cancer technologies
Read more at:
http://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel
Related posts
